S
udden cardiac arrest (CA) is a leading cause of death worldwide. 1 Despite advances in cardiopulmonary resuscitation (CPR) methods, including the introduction of the automatic electric defibrillator and targeted temperature management, only 10% to 20% of adult out-of-hospital CA victims survive to hospital discharge. Up to 60% of those survivors have moderate to severe cognitive deficits 3 months after resuscitation. 2 Post-CA syndrome is a unique and complex combination of pathophysiological processes, including brain injury, myocardial dysfunction, and systemic inflammatory responses. 3, 4 Although the greatest proportion of post-CA mortality and morbidity is caused by global ischemic brain injury, 3 the severity of both myocardial dysfunction and systemic inflammation correlates with poor neurological outcome. 3, 4 The mechanisms responsible for post-CA brain injury include excitotoxicity, free radical formation, endothelial dysfunction, and cell death signaling. 3, 5 There is currently no pharmacological treatment that has been proven to improve outcomes after CA and CPR (CA/CPR). 5 Nitric oxide (NO) bioactivity prevents organ injury induced by ischemia and reperfusion (I/R). Administration of NO via inhalation [6] [7] [8] [9] or by using a NO-donating compound 10 improves the outcomes after CA/CPR in multiple species. Moreover, genetic deletion of NO synthase 3 (NOS3) abolished the protective effects of mild hypothermia in mice resuscitated from CA, 7 suggesting a critical role of NO in targeted temperature management, the single most effective intervention to improve outcomes in post-CA patients. However, mechanisms responsible for the protective effects of NO-dependent signaling during recovery after CA/CPR are incompletely understood.
The biological effects of NO are mediated primarily via activation of guanylyl cyclase (GC; and consequent production of cyclic guanosine monophosphate [cGMP]) or protein S-nitrosylation, [11] [12] [13] the covalent attachment of NO to cysteine residues of target proteins. Both of these mechanisms have been implicated in the protective effects of NO in I/R. For example, we have previously reported that inhaled NO improves outcomes after CA/CPR in a GC-dependent manner. 6 Strategies that increase levels of S-nitrosothiols have been reported to mitigate I/R injury of the brain and heart.
14-18 S-nitrosoglutathione (GSNO) is one of the more abundant Snitrosothiols in plasma and other tissues, and serves as an important reservoir of bioactive NO. A potent antioxidant, GSNO also blocks inflammation and secondary injury in the brain after I/R in animal models. 18, 19 Reduction of GSNO by a denitrosylase, S-nitrosoglutathione reductase (GSNOR), decreases the intracellular levels of the protein S-nitrosylation, as GSNO and S-nitrosylated proteins are in equilibrium. 20, 21 GSNOR is expressed in all human tissues including brain, liver, and vascular endothelial and smooth muscle cells. 22 Pharmacological inhibition or genetic deletion of GS-NOR increases tissue levels of S-nitrosothiols and causes vasodilation, [23] [24] [25] consistent with the role of GSNO in conveying the NO activity. Inhibition of GSNOR has been shown to induce protein S-nitrosylation and decrease inflammation. 24, 26 After permanent left coronary artery ligation, GSNOR-deleted (GSNOR −/− ) mice exhibited attenuated myocardial injury and improved myocardial function compared with wild-type (WT) mice. 25 The beneficial effects of GSNOR deletion were associated with enhanced angiogenesis because of stabilization of hypoxia-inducible factor 1α via S-nitrosylation. 25 Deletion of GSNOR increased protein-bound NO, decreased CD4 + and CD8 + T-cells in the brain, and improved blood-brain barrier (BBB) integrity, neurological function, and survival in a mouse model of cerebral malaria. 27 Although these observations suggest salutary effects of GSNOR inhibition against systemic and brain inflammation and ischemic myocardial injury, the role of GSNOR on outcomes after CA/CPR remains to be determined.
To elucidate the impact of GSNOR on outcomes after CA/CPR, we evaluated the effects of both a selective GSNOR inhibitor and genetic deletion of GSNOR on survival and neurological outcomes after CA/CPR in
Clinical Perspective
What Is New?
• This is the first study to show that ischemia and reperfusion induced by cardiac arrest and cardiopulmonary resuscitation in mice activates S-nitrosoglutathione reductase (GSNOR) in plasma and multiple organs including brain in particular.
• Activation of GSNOR after cardiac arrest and resuscitation reduced protein S-nitrosylation in the brain that decreases the bioavailability of nitric oxide. • Post-cardiac arrest patients had higher plasma GSNOR activity than did preoperative cardiac surgery patients or healthy volunteers.
• Pharmacological inhibition or genetic deletion of GSNOR prevents brain injury and improves neurological outcomes and survival in mice resuscitated from experimental cardiac arrest.
What Are the Clinical Implications?
• GSNOR activity may prove to be a useful biomarker of postarrest brain injury as well as a therapeutic target to improve survival and neurological outcomes after cardiac arrest.
• Strategies to inhibit GSNOR or increase protein S-nitrosylation may preserve nitric oxide bioavailability and prevent organ injury in patients recovering from sudden cardiac arrest or other forms of ischemia and reperfusion injury.
A specific GSNOR inhibitor SPL-334.1 (supplied by SAJE Pharma, LLC) was discovered by Sanghani et al as compound 24 and developed by SAJE Pharma, LLC for in vivo use as a sodium salt. WT mice were subjected to CA and received either SPL-334.1 (6 mg/kg) or the same volume (100 µL) of normal saline (placebo) intravenously at 15 minutes after return of spontaneous circulation (ROSC) in a randomized and blinded manner. SPL-334.1 was dissolved in sterile distilled water, pH 8.0, adjusted with 1 mol/L NaHCO 3 . Because we found that mice treated with normal saline or distilled water had similar survival rates and inflammatory response after CA/CPR in pilot experiments, we used normal saline as placebo.
To minimize variability, we used randomized paired (aka, matched pairs) design. 11 We paired inbred C57BL/6 mice to SPL-334.1 or placebo on the basis of similar weight, age, delivery date, and when possible holding cage. Pairing appeared effective (Table I in online-only Data Supplement). Shamoperated mice received anesthesia, surgery, and ventilation but no CA and the same postresuscitation care until the similarly timed end point. Sham-operated mice were drawn from the same batch as experimental animals in all experiments except for plasma cytokine measurements. Plasma GSNOR activity was measured in post-CA GSNOR -/-mice as negative control in an unblinded manner.
Measurements of GSNOR Activity
We measured GSNOR activity at 6 hours after CA/CPR based on pilot experiments (data not shown). The rate of GSNOdependent NADH consumption was measured to assess GSNOR activity levels in plasma and tissue homogenates, as previously described. 20, 30 Samples were homogenized in a buffer containing (in mmol/L) 50 Tris-HCl (pH 8.0), 150 NaCl, 1 EDTA, 0.1% Triton X-100, and 1:100 protease inhibitor cocktail. After centrifugation for 10 minutes at 10 000g, samples were diluted to a protein concentration of 0.1 mg/mL or a plasma concentration of 1.0 mg/mL in reaction buffer containing 20 mmol/L Tris-HCl (pH 8.0), 0.5 mmol/L EDTA, and incubated with 75 μmol/L NADH with or without 100 μmol/L GSNO. NADH consumption was monitored by fluorescence spectrophotometry with excitation at 340 nm and emission at 460 nm. GSNOR activity was defined as the rate of NADH consumption in samples incubated in the presence of GSNO minus the rate of NADH consumption without GSNO.
Assessment of Neurological Function
Neurological function score was assessed at 96 hours after CA/CPR by an investigator blinded to the experimental group using a previously-reported neurological function scoring system with minor modifications. 6, 7, 28, 29 Dead mice were scored at 0 points. Dead mice were excluded from the statistical analysis.
S-Nitrosylated Protein and Peptide Identification After CA/CPR
Total S-nitrosylated proteins were detected by resin-assisted capture of S-nitrosylated proteins, as previously described. 31 Label-free peptide identification and quantification was then performed with a liquid chromatography-tandem mass spectrometry system (LTQ Orbitrap XL mass spectrometer; Thermo Fisher Scientific) at the Taplin Biological Mass Spectrometry Facility (Harvard Medical School). Peptide and protein identifications were extracted from the Sequest database using default settings. Peptides were counted if they were recovered in any single sample, and were counted only once per experimental group. Proteins were considered present if ≥2 supporting peptides were recovered. Proteins recovered from multiple replicates per experimental group were counted only once. We reported the number of unique peptides and proteins identified in each experimental group, as previously shown by others. 32 Abundance of S-nitrosylated proteins for each replicate was determined as the sum of peptide peak area intensity for all recovered peptides corresponding to each protein analyzed. For proteins present in all 3 samples of each treatment group, we used t tests to compare the abundance of recovered proteins between placebo-treated and SPL-334.1-treated WT mice or between placebo-treated WT mice and GSNOR −/− mice. Detailed descriptions of reagents and the protocols for murine CA model, multiplex cytokines/chemokines assay, measurements of hydrogen peroxide, cerebral blood flow (CBF), SPL-334.1 concentrations, histological studies, Evan's blue assay, detailed work flow of resin-assisted capture of S-nitrosylated proteins followed by liquid chromatographytandem mass spectrometry, and Reactome pathway analysis are provided in the online-only Data Supplement Methods.
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Human Subjects
We obtained convenience plasma samples of post-CA patients at Massachusetts General Hospital and Beth Israel Deaconess Medical Center, Boston, MA. Inclusion criteria consisted of adult (age >18 years) patients who had ROSC after an outof-hospital CA. Blood was drawn within 6 to 8 hours of sustained ROSC into citrated tubes and centrifuged within 30 minutes to separate plasma. Aliquots were stored at −80°C until analysis. CA of traumatic etiology was excluded as were patients considered a protected population. Healthy volunteers and preoperative cardiac surgery patients as controls were enrolled at Massachusetts General Hospital. The institutional review board at Massachusetts General Hospital and Beth Israel Deaconess Medical Center approved the study and all subjects or their legally authorized surrogate provided written informed consent.
Statistical Analysis
Data for continuous variables are presented as means with SEM or medians with interquartile range. Categorical data are presented as counts with frequencies. An unpaired 2-tailed Student t test or Mann-Whitney U test was used to compare 2 independent groups, as appropriate, for continuous variables. One-way or 2-way ANOVA followed by Sidak correction for post hoc comparisons and Kruskal-Wallis test followed by Dunn multiple comparisons were used for post hoc comparisons for normally distributed data and nonnormally distributed data, respectively. In 3 group comparisons, post hoc comparisons were performed only in comparisons between sham versus placebo and placebo versus SPL-334.1. To compare the nonnormally distributed data in each time point between groups, Friedman test followed by Dunn multiple comparisons were used for post hoc comparisons. Survival rates were estimated using the Kaplan-Meier method and log-rank test was used to compare the survival curves between groups. As the mean survival rate at 6 days after CA was expected as 25% in WT and placebo-treated WT mice, 80% in GSNOR −/− and SPL-334.1-treated WT mice, we anticipated that 11 mice per group were required in each survival study (α=0.05, β=0.2 [Power=80%], two-sided). For measurements of GSNOR activity, by using Cohen F statistics based on our pilot study, we anticipated that 8 mice per group were required to determine the mean differences across 3 groups (α=0.05, β=0.2 [Power=80%], 2-sided). In human study, we used Spearman correlation coefficient (r s ) to determine the association between the GSNOR activity and lactate levels in plasma. Significance was considered at the level of P<0.05. GraphPad Prism 7.0 (GraphPad Software Inc, La Jolla, CA) and SPSS 23.0 (SPSS Inc, Chicago, IL) were used for statistical analyses.
RESULTS
Administration of SPL-334.1, a GSNOR Inhibitor, After ROSC Prevented Brain Injury and Improved Survival After CA in Mice
There was no difference in the perioperative parameters between postarrest mice treated with placebo or SPL-334.1 (Table I in the online-only Data Supplement). The survival rate in placebo-treated mice was 36.4% (4 of 11) at 6 days after CA/CPR. Treatment with SPL-334.1 15 minutes after ROSC improved survival rates to 81.8% (9 of 11; log rank P=0.031 versus placebo, Figure 1A ). Neurological function score was higher in SPL-334.1-treated mice than in placebo-treated mice at 96 hours after CA/CPR (P=0.011 by Mann-Whitney U test, Figure 1B ). CA and CPR increased the ratio of Fluoro-Jade B-positive neurons in all cells in the cortex, caudoputamen, and hippocampus in placebo-treated mice at 24 hours after CA/CPR. Administration of SPL-334.1 abated the increase of Fluoro-Jade B positive cells in the brain regions ( Figure 1C and 1D) .
GSNOR Activity Was Increased in Multiple Organs After CA and CPR
To evaluate the role of GSNOR in the pathogenesis of CA/CPR, we examined GSNOR activity in plasma, brain, heart, liver, and spleen of mice after CA/CPR. Plasma GSNOR activity in placebo-treated mice significantly increased at 6 hours after CA/CPR compared with sham-operated mice. As expected, post-CA GS-NOR −/− mice exhibited no GSNOR activity in plasma (Figure 2A ). CA and CPR increased GSNOR activity in brain, liver, and spleen at 6 hours after CA/CPR (Figure 2B, 2D , and 2E). There was a trend toward increased GSNOR activity in heart at 6 hours after CA/ CPR (P=0.092, Figure 2C ). CA and CPR did not affect protein levels of GSNOR in the brain and heart at 6 hours after CPR (data not shown). Administration of SPL-334.1 markedly reduced GSNOR activity in plasma, brain, heart, liver, and spleen compared with placebo-treated mice at 6 hours after CA/CPR (Figure 2A through 2E) .
GSNOR-Deletion Prevented Ischemic Brain Injury and Improved Survival After CA/CPR in Mice
There was no statistical difference in the perioperative parameters between WT and GSNOR −/− mice except for mean arterial pressure at baseline and the time of ROSC (Table II in the online-only Data Supplement). The survival rate was 16.7% (2 of 12) in WT mice at 6 days after CA/CPR. GSNOR-deletion improved survival rates to 66.7% (8 of 12; log rank P=0.036 versus WT, Figure 3A) . Neurological function was better in GSNOR −/− than in the WT mice at 96 hours after CA/ CPR (P=0.026 by Mann-Whitney U test, Figure 3B Figure 3C and 3D). These results indicate that GSNOR deletion prevents ischemic brain injury and improves survival after CA/CPR in mice.
Pharmacological Inhibition or Congenital Deletion of GSNOR Increased the Number of S-Nitrosylated Proteins in the Brain After CA/CPR
To determine the impact of changes in GSNOR activity on protein S-nitrosylation after CA/CPR, we sought to identify S-nitrosylated proteins in brain and liver of WT mice subjected to sham operation or CA/ CPR and treated with SPL-334.1 or placebo and GS-NOR −/− mice subjected to CA/CPR, using resin-assisted capture of S-nitrosylated proteins followed by liquid chromatography-tandem mass spectrometry. CA and CPR decreased the number of S-nitrosylated proteins and peptides in the brain of placebo-treated WT mice (Figure 4) . Administration of SPL-334.1 or GSNOR-deletion restored the number of S-nitrosylated proteins in the brain to the levels in sham-operated mice. CA and CPR did not affect the number of S-nitrosylated proteins in liver of mice with or without GSNOR inhibition or deletion ( Figure I and Table III in the onlineonly Data Supplement). When we compared the identity of S-nitrosylated proteins between the brains of placebo-treated WT, SPL-334.1-treated WT, and GS- 
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NOR −/− mice at 6 hours after CA/CPR, there were 226 proteins that were recovered in SPL-334.1-treated WT or GSNOR −/− mice, but not in placebo-treated WT mice ( Figure 4D ). Among these 226 S-nitrosylated proteins, 76 proteins were detected both in SPL-334.1-treated mice and GSNOR −/− mice ( Figure 4D ). Among the 285 S-nitrosylated proteins that were detected in the brains of both placebo-treated and SPL-334.1-treated WT mice, abundance of 18 proteins were greater (P<0.05) in SPL-334.1-treated than in placebo-treated WT mice. These 244 (226+18) proteins are listed in Table IV in the online-only Data Supplement. It is of note that 17.2% (42 of 244) of these proteins are mitochondrial proteins.
To identify pathways that were most impacted by protein S-nitrosylation induced by SPL-334.1 or GS-NOR-deficiency after CA/CPR, we performed pathway analysis of the 244 proteins using Reactome (version 65; https://reactome.org/(08/10/2018)). 33 Ten pathways were found to be highly enriched in the list of S- A, Plasma GSNOR activity in sham-operated mice and post-CA wild-type mice treated with placebo or SPL-334.1 (n=8 each), and post-CA GSNOR −/− mice (n=11). One-way ANOVAs followed by Sidak corrections were used to test statistical difference. B through E, GSNOR activity in brain, heart, liver, and spleen of sham-operated mice and wild-type mice 6 hours after CA/CPR treated with placebo or SPL-334.1. n=8 for each group. For brain, heart, and liver, 1-way ANOVAs followed by Sidak corrections were used to test statistical difference. For spleen, Kruskal-Wallis test followed by Dunn multiple comparisons was used to test statistical difference. Data are presented as mean±SEM.
Circulation. Table V in the online-only Data Supplement, Data Files I and II in the online-only Data Supplement). Remarkably, 7 of the top 10 pathways are concentrated in 2 broad categories: the citric acid cycle and respiratory electron transport (3 pathways) and vesicle-mediated transport (4 pathways). These observations suggest that pharmacological inhibition or genetic deletion of GSNOR modulate multiple cellular signaling pathways by increasing the levels of protein S-nitrosylation in the brain after CA/CPR.
GSNOR Inhibition Attenuated Plasma Cytokine/Chemokine Levels Early After CA/CPR
To assess the mechanisms responsible for the beneficial effects of GSNOR inhibition on outcomes after CA/ CPR, we examined plasma cytokine/chemokine levels in post-CA mice treated with SPL-334.1 or placebo compared with sham-operated mice drawn from a separate batch as unblinded control. CA and CPR increased the plasma levels of interleukin (IL)-6, keratinocyte chemoattractant, monokine induced by γ interferon, IL-12, IL-1β, macrophage inflammatory protein-1α, monocyte 
GSNOR Deletion Attenuated Oxidative Stress in the Brain Early After CA/CPR
Levels of oxidative stress in the whole brain were assessed by measuring hydrogen peroxide in the brain tissue homogenates in GSNOR -/-and WT mice after sham operation or CA/CPR. Brain levels of hydrogen peroxide were significantly increased at 5 minutes after CA/ CPR in WT mice. GSNOR deletion prevented the CA/ CPR-induced increase of hydrogen peroxide in the brain ( Figure 5D ). There was no difference in cytokine/chemokine levels between WT and GSNOR −/− mice, except for higher levels of monokine induced by γ interferon in GSNOR −/− mice at 6 hours after CA/CPR ( Figure III in the online-only Data Supplement). There was no difference in CBF within the first 4 hours after ROSC between WT mice and GSNOR −/− mice ( Figure IV in the online-only Data Supplement). These observations suggest that protective effects of GSNOR deletion after CA/CPR were associated with attenuated oxidative stress in the brain.
GSNOR Inhibition or Deletion Prevented Blood-Brain Barrier Disruption After CA/ CPR
To further characterize the mechanism of neuroprotection by GSNOR inhibition and deletion, we assessed the permeability of BBB in sham-operated mice, postarrest WT mice treated with placebo or SPL-334.1, and postarrest GSNOR -/-mice using the Evan blue assay. CA and Figure 7) . We analyzed the correlation between GSNOR activity and initial lactate levels. 34 After excluding one patient with missing lactate level data, the plasma GSNOR activity was found to be positively correlated with lactate levels in post-CA patients (r s =0.48, P=0.045; Figure 
DISCUSSION
The current study revealed that GSNOR enzyme activity was increased in multiple organs in mice resuscitated from experimental CA. Administration of a GSNOR inhibitor, SPL-334.1, at 15 minutes after ROSC attenuated the increase in GSNOR activity, prevented ischemic brain injury, and markedly improved neurological function and survival rate after CA/CPR in mice. The beneficial effects of the post-CPR GSNOR inhibition were associated with preservation of protein S-nitrosylation in the brain and attenuation of systemic inflammation. Similarly, genetic deletion of GSNOR maintained the number of S-nitrosylated proteins in the brain, attenuated oxidative stress, and improved neurological outcomes and survival after CA/CPR. Both SPL-334.1 and GSNOR deletion improved BBB integrity after CA/CPR. Moreover, in an observational human study, plasma GSNOR activity early after resuscitation was markedly higher in post-CA patients compared with those in healthy volunteers and preoperative cardiac surgery patients. Taken together, these observations indicate that the inhibition of GSNOR is a novel molecular target to improve neurological outcomes after CA/CPR. 
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NO-dependent signaling plays a pivotal role in cellular communication and homeostasis. Because GSNO serves as a main reservoir of cellular S-nitrosothiol species that govern NO bioavailability in vivo, 35, 36 accelerated GSNO metabolism by GSNOR has dire consequences on cellular function and survival. Aberrant increases in GSNOR activity or reduction in RSNO levels (including GSNO and S-nitrosylated proteins) have been reported in animal models of many human diseases including asthma, 37 idiopathic pulmonary fibrosis, 26 myocardial infarction, 38 and cerebral malaria. 27 In contrast, administration of GSNO has been shown to inhibit neuroinflammation and secondary brain injury after cerebral I/R and traumatic brain injury. 18, 39 Along these lines, the current study showed that GSNOR activity is increased while Snitrosylated protein levels are decreased in the post-CA brain. Pharmacological GSNOR inhibition after ROSC or genetic GSNOR-deletion maintained the levels of Snitrosylated proteins in the brain at 6 hours after CA/ CPR to similar levels observed in sham-operated mice. These results are consistent with previous observations that NO metabolites (measured as plasma nitrite) were decreased in mice after CA/CPR, whereas restoration of NO bioactivity exerted salutary effects. 7, 11 The number of S-nitrosylated proteins was markedly higher in the liver than in the brain at baseline despite approximately 3-fold higher basal GSNOR activity in the liver than in the brain. Liver GSNOR activity was increased by CA/CPR in placebo-treated mice while administration of SPL-334.1 prevented the CA/CPR-induced increase of liver GSNOR activity. However, levels of S-nitrosylated proteins in the liver were not affected by CA/CPR either with placebo or SPL-334.1 treatment. These results suggest a relatively minor role of GSNOR in controlling the levels of protein S-nitrosylation in the liver after CA/CPR. It is possible that levels of Snitrosylated proteins are determined predominantly by a higher rate of NO production or other denitrosylating enzymes in the liver, including thioredoxin-related proteins and SNO-CoA reductases. 40 Levels of GSNOR activity in the brain can be increased after CA/CPR as a result of direct activation of GSNOR in native brain cells (eg, neurons, astrocytes, vascular endothelial cells), as well as a result of infiltration of bloodborne cells with activated GSNOR through disrupted BBB. Accordingly, there are 2 possible mutually-nonexclusive mechanisms of action whereby SPL-334.1 mitigates the increase of GSNOR activity in the brain after CA/CPR. Because SPL-334.1 appears to reach the brain, albeit at relatively low concentrations after CA/CPR (Figure VI and Table VII in the online-only Data Supplement), it is possible that SPL-334.1 directly inhibited GSNOR in native brain cells early after CPR thereby prevented the reduction of S-nitrosylated proteins in the brain 6 hours after CA/CPR. Alternatively, it is conceivable that SPL-334.1 inhibited GSNOR activation and concomitant reduction of RSNO primarily in the vascular compartment. Maintaining normal RSNO levels prevents vascular endothelial dysfunction and disruption of BBB while inhibiting activation and infiltration of immune cells and platelets into the brain. 27, 41 The observation that both SPL-334.1 and GSNOR deletion prevented BBB disruption after CA/CPR supports the latter hypothesis. 
A number of proteins have been proposed as targets of S-nitrosylation that may mediate protective effects of protein S-nitrosylation after I/R injury. The proposed S-nitrosylation targets include, but not limited to, ND3 subunit of mitochondrial complex I, sarcoplasmic reticulum Ca 2+ -ATPase, α-ketoglutarate dehydrogenase, and the mitochondrial F1-ATPase α1 subunit. 17, 42 Of note, many mitochondrial proteins are included in the list of the target proteins of S-nitrosylation. 16, 17, 42 In the current study, 17.2% of S-nitrosylated proteins that were enriched in SPL-334.1-treated WT or GSNOR −/− mice, but not in placebo-treated WT mice, after CA/CPR are mitochondrial proteins (Table IV in the online-only Data Supplement). Reactome pathway analysis identified mitochondrial pyruvate metabolism and the citric acid cycle, as well as respiratory electron transport, as one of the most S-nitrosylated pathway categories in the brains of SPL-334.1-treated WT or GSNOR -/-mice compared with placebo-treated WT mice after CA/ CPR. Impaired mitochondrial bioenergetics jeopardizes not only neuronal survival, but also endothelial function and BBB integrity. 43 Fiskum et al reported that oxidative inhibition of pyruvate dehydrogenase complex contributes to energy failure and brain injury after CA/ CPR. 44 It is conceivable that enhanced S-nitrosylation may protect pyruvate dehydrogenase complex and other enzymes in the citric acid cycle from irreversible oxidation. 45 Chouchani et al reported that reversible Snitrosylation protects mitochondrial electron transport chain complex I from irreversible oxidation thereby attenuates myocardial I/R injury. 17 The current observation that neuroprotective effects of GSNOR deletion were associated with preserved S-nitrosylation and inhibition of ROS production in the post-CA brain corroborates the protective role of S-nitrosylation on mitochondrial function after I/R.
The pharmacological inhibition or deletion of GS-NOR has been reported to mitigate inflammation 24, 26 and oxidative stress. 46, 47 In the current study, administration of SPL-334.1 appeared to attenuate the increments of plasma IL-6, keratinocyte chemoattractant, and monokine induced by γ interferon, but not other cytokines/chemokines, at 6 hours after CA/CPR. Congenital deletion of GSNOR attenuated the CA/CPRinduced increase of ROS in the brain, but not plasma cytokines/chemokines levels. The altered response to systemic inflammation in GSNOR -/-mice may be caused by the excessive apoptosis in thymus compromising development and survival of B and T lymphocytes. 48 Additional studies are required to determine whether or not anti-inflammatory effects play a major role in the beneficial effects of GSNOR inhibition or deletion after CA/CPR.
From the viewpoint of clinical translation, we believe that our findings-beneficial effects of SPL-334.1 are achieved with a single intravenous administration at 15 minutes after ROSC-may have important clinical implications. Although SPL-334.1 has not been tested in clinical trials, several clinical trials with other GSNOR inhibitors (N6022 and N91115; Nivalis Therapeutics Inc) have been completed. The trials showed that the GSNOR inhibitors were safe and well tolerated after intravenous administration in healthy volunteers (NCT01147406, NCT01339897) and in adult patients with mild asthma (NCT01316315) or cystic fibrosis (NCT01746784, NCT02724527). These results suggest that the GSNOR inhibition, as a mechanism of action, is safe and may exert therapeutic effects in human.
We recognize several limitations of our study. First, we used normal saline as placebo based on our pilot studies in which mice treated with normal saline or water at pH 8.0 (vehicle of SPL-334.1) exhibited comparable outcomes after CA/CPR. Second, this study limited to a single sex (male) may not yield a complete understanding of the role of GSNOR in post-CA syndrome. Third, cytokine measurements in sham-operated mice were conducted at a different time from cytokine measurements in postarrest mice. Therefore, cytokine measurements in sham-operated mice were not blinded or batch-randomized, whereas all other mouse experiments in this study, including the treatment (placebo versus SPL334.1) and cytokine measurements in postarrest mice, were conducted in a fully-blinded and batchrandomized manner. Finally, the human study was performed in a retrospective observational manner. It is possible that, in addition to the postarrest status, other uncontrolled confounding factors (eg, comorbidities) may have affected GSNOR activity. The potential role of GSNOR activity as a biomarker of the post-CA outcomes remains to be confirmed in a prospective study of a larger sample size.
In conclusion, the current study revealed protective effects of a GSNOR inhibitor and GSNOR-deletion on neurological and survival outcomes after CA/CPR in mice. Our observations suggest that inhibition of GS-NOR may prevent ischemic brain injury after CA/CPR by enhancing protein S-nitrosylation in the brain. Further studies are warranted to elucidate the role of GSNOR inhibition on ischemic brain injury not only after CA and CPR, but also in ischemic stroke, spinal cord injury, traumatic brain injury, and perhaps neurodegenerative diseases. 
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